- Citibank Biotech’s
Mood Disorders/Mental Health Panel - Taking place virtually on
May 18 th, 2022 at11:00 am ET
- Taking place virtually on
Berenberg Capital Markets Emerging Biotech Conference - Taking place virtually and in-person in
San Francisco onMay 19 th, 2022
- Taking place virtually and in-person in
H.C. Wainwright Global Investment Conference - Taking place virtually and in-person in
Miami Beach fromMay 23 rd - 26th
- Taking place virtually and in-person in
An audio webcast link for each event, when available, will be posted to Bionomics’ website in the Investors-Events and Presentations section.
FOR FURTHER INFORMATION PLEASE CONTACT:
General Ms Company Secretary +61 8 8150 7400 CoSec@bionomics.com.au | Investor Relations Mr. Vice President, Strategy and Corporate Development +1 (650) 524-5143 cbernstein@bionomics.com.au | Investor Relations kgardner@lifesciadvisors.com |
About
Bionomics (ASX:BNO, NASDAQ:BNOX) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious CNS disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside
www.bionomics.com.au
Source:
2022 GlobeNewswire, Inc., source